Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Arcutis Biotherapeutics Inc shares valued at $332,851 were sold by Burnett Patrick on Dec 15 ’25. At $28.94 per share, Burnett Patrick sold 11,500 shares. The insider’s holdings dropped to 98,307 shares worth approximately $2.79 million following the completion of this transaction.
Also, Patrick Burnett purchased 11,500 shares, netting a total of over 332,851 in proceeds.
Before that, Matsuda Masaru had sold 1,657 shares from its account. In a trade valued at $50,091, the insider traded Arcutis Biotherapeutics Inc shares for $30.23 each. Upon closing the transaction, the insider’s holdings decreased to 1,657 shares, worth approximately $4.27 million.
As published in their initiating research note from Goldman on July 25, 2025, Arcutis Biotherapeutics Inc [ARQT] has been a Neutral and the price target has been revised to $18. Analysts at H.C. Wainwright started covering the stock with ‘”a Buy”‘ outlook in a report released in late December. As of August 28, 2024, Jefferies has initiated its “Buy” rating for ARQT. Earlier on January 03, 2024, Mizuho upgraded its rating. Their new recommendation was “a Buy” for ARQT stock which previously was a “a Neutral”.
Analyzing ARQT Stock Performance
On last trading session, Arcutis Biotherapeutics Inc [NASDAQ: ARQT] plunged -0.67% to $28.34. The stock’s lowest price that day was $28.05, but it reached a high of $28.69 in the same session. During the last five days, there has been a drop of approximately -4.80%. Over the course of the year, Arcutis Biotherapeutics Inc shares have jumped approximately 123.33%. Shares of the company reached a 52-week high of $31.77 on 12/08/25 and a 52-week low of $11.13 on 02/11/25.
Support And Resistance Levels for Arcutis Biotherapeutics Inc (ARQT)
According to the 24-hour chart, there is a support level at 28.03, which, if violated, would cause prices to drop to 27.72. In the upper region, resistance lies at 28.67. The next price resistance is at 29.00. RSI (Relative Strength Index) is 51.18 on the 14-day chart, showing neutral technical sentiment.
Is Arcutis Biotherapeutics Inc subject to short interest?
Stocks of Arcutis Biotherapeutics Inc saw a sharp steep in short interest on 2025-11-28 dropping by -1.42 million shares to 12.06 million. Data from Yahoo Finance shows that the short interest on 2025-10-31 was 13.48 million shares. A decline of -11.77% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 3.77 of the overall float, the days-to-cover ratio (short ratio) decline to 3.77.
Which companies own the most shares of Arcutis Biotherapeutics Inc (ARQT)?
In terms of Arcutis Biotherapeutics Inc share price expectations, FactSet research, analysts set an average price target of 30 in the next 12 months, up nearly 5.15% from the previous closing price of $28.53. Analysts anticipate Arcutis Biotherapeutics Inc stock to reach 37 by 2025, with the lowest price target being 29. In spite of this, 3 analysts ranked Arcutis Biotherapeutics Inc stock as Buy at the end of 2025. On October 26, 2023, Mizuho assigned a price target of “a Neutral” to the stock and downgraded coverage with a $4.
